Journal
CANCER DISCOVERY
Volume 7, Issue 4, Pages 369-379Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-16-0330
Keywords
-
Categories
Funding
- Janssen
- NIH [CA195173, CA136895]
- Lymphoma Research Foundation
- Hertz Foundation Fellowship
- National Science Foundation Graduate Research Fellowship
Ask authors/readers for more resources
Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we defi ne recurrently mutated driver genes and copy-number alterations in the disease. Chromatinmodifying genes, including SETD2, INO80, and ARID1B, were commonly mutated in HSTL, affecting 62% of cases. HSTLs manifest frequent mutations in STAT5B (31%), STAT3 (9%), and PIK3CD (9%), for which there currently exist potential targeted therapies. In addition, we noted less frequent events in E ZH2, KRAS, and T P53. S ETD2 was the most frequently silenced gene in HSTL. We experimentally demonstrated that SETD2 acts as a tumor suppressor gene. In addition, we found that mutations in STAT5B and PIK3CD activate critical signaling pathways important to cell survival in HSTL. Our work thus defi nes the genetic landscape of HSTL and implicates gene mutations linked to HSTL pathogenesis and potential treatment targets. SIGNIFICANCE: We report the first systematic application of whole-exome sequencing to define the genetic basis of HSTL, a rare but lethal disease. Our work defines SETD2 as a tumor suppressor gene in HSTL and implicates genes including INO80 and PIK3CD in the disease. (C) 2017 AACR
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available